

DAFTAR PUSTAKA

1. Šeruga M, Makuc J, Završnik M, Cilenšek I, Ekart R, Petrovič D. Polymorphism of angiotensin-converting enzyme (rs4340) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus. *Balk J Med Genet*. 2016 Dec 31;19(2):29–34.
2. Mihardja L, Delima D, Massie RGA, Karyana M, Nugroho P, Yunir E. Prevalence of kidney dysfunction in diabetes mellitus and associated risk factors among productive age Indonesian. *J Diabetes Metab Disord*. 2018 Jun;17(1):53–61.
3. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. *Nat Rev Dis Primer*. 2015 Dec 17;1(1):15018.
4. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. *Clinical Journal of the American Society of Nephrology*. 2017 Dec 7;12(12):2032-2045. Doi: 10.2215/CJN.11491116.
5. Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: Diabetic kidney disease versus nondiabetic kidney disease. *Nature Reviews Nephrology*. 2018 Jun;14(6):361-377.doi: 10.1038/s41581-018-0001-y.
6. Mooyaart AL. Genetic associations in diabetic nephropathy. *Clin Exp Nephrol*. 2014 Apr;18(2):197–200.
7. Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occluding expression and tight junction assembly. *Am J Physiol-Heart Circ Physiol*. 2001 Jan 1;280(1):H434–40.
8. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. *Nat Med*. 2007 Nov;13(11):1349–58.
9. Tufro A, Veron D. VEGF and Podocytes in Diabetic Nephropathy. *Semin Nephrol*. 2012 Jul;32(4):385–93.

10. The role of VEGF rs699947 polymorphism in End-Stage Renal Disease: A preliminary study. *Kastamonu Med J.* 2021 Mar 30;19–23.
11. Bassar IK, Jamsari J, Nasrul E, Humaryanto H. Relationship between Gene Polymorphism of Vascular Endothelial Growth Factor (VEGF) rs699947 with VEGF and Matrix Metalloproteinase-14 Protein Levels in Patient with Diabetic Foot Ulcer. *Open Access Maced J Med Sci.* 2022 Apr 29;10(A):720–4.
12. Alvin C. Powers. Diabetes Melitus in Kasper, et al editors. *Harrison's The Principle of the Internal Medicine.* 19th ed. United States :McGrawHill Education; 2015. Hal 2413-22
13. Kumar V., Abbas A. K., Aster, J. C., 2015 *Buku Ajar Patologi Robbins.* Singapura: Elsevier. Ed 9th. pp 297.
14. World Health Organization. Global status report on non communicable diseases 2014. WHO; 2014. (diakses 14Maret 2020) Diunduh dari [URL:http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf](http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf)
15. International Diabetes Federation. *Diabetes atlas sixth edition.* IDF; 2015
16. Keri KC, Samji NS, Blumenthal S. Diabetic nephropathy: newer therapeutic perspectives. *J Community Hosp Intern Med Perspect.* 2018 Jul 4;8(4):200–7.
17. Hussain S, Chand Jamali M, Habib A, Hussain MS, Akhtar M, Najmi AK. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. *Clin Epidemiol Glob Health.* 2021 Jan;9:2–6.
18. Reutens AT, Atkins RC. Epidemiology of Diabetic Nephropathy. In: Lai KN, Tang SCW, editors. *Contributions to Nephrology [Internet].* Basel: KARGER; 2011 [cited 2022 May 19]. p. 1–7. Available from: <https://www.karger.com/Article/FullText/324934>

19. Qi C, Mao X, Zhang Z, Wu H. Classification and Differential Diagnosis of Diabetic Nephropathy. *J Diabetes Res*. 2017;2017:1–7.
20. Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KAM, Zoungas S, et al. Diabetic kidney disease. *Nat Rev Dis Primer*. 2015 Dec 17;1(1):15018.
21. Khoury CC, Chen S, Ziyadeh FN. Pathophysiology of Diabetic Nephropathy. In: *Chronic Renal Disease* [Internet]. Elsevier; 2015 [cited 2022 May 19]. p. 151–62. Available from: <https://linkinghub.elsevier.com/retrieve/pii/B9780124116023000135>
22. Koye DN, Shaw JE, Reid CM, Atkins RC, Reutens AT, Magliano DJ. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. *Diabet Med*. 2017 Jul;34(7):887–901.
23. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract*. 2019 Nov;157:107843.
24. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. *Kidney Int*. 2006 Jun;69(11):2057–63.
25. He F, Xia X, Wu XF, Yu XQ, Huang FX. Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis. *Diabetologia*. 2013 Mar;56(3):457–66.
26. Parving HH, Gall MA, Skøtt P, Jørgensen HE, Løkkegaard H, Jørgensen F, et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. *Kidney Int*. 1992 Apr;41(4):758–62.
27. Selby NM, Taal MW. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. *Diabetes Obes Metab*. 2020 Apr;22(S1):3–15.

28. American Diabetes Association. 11. Microvascular Complications and Foot Care: *Standards of Medical Care in Diabetes—2019*. Diabetes Care. 2019 Jan 1;42(Supplement_1):S124–38.
29. Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019 Jan;15(1):45–59.
30. McMillin JM. Blood Glucose. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990.
31. Marks D, Marks A, Smith C. Biokimia Kedokteran Dasar. Jakarta: Penerbit Buku Kedokteran EGC; 2012.
32. Triplitt CL. Understanding the kidneys’ role in blood glucose regulation. Am J Manag Care. 2012 Jan;18(1 Suppl):S11-16.
33. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of Diabetes and Diabetes-Related Complications. Phys Ther. 2008 Nov 1;88(11):1254–64.
34. Abdulla H, Phillips B, Smith K, Wilkinson D, Atherton P, Idris I. Physiological Mechanisms of Action of Incretin and Insulin in Regulating Skeletal Muscle Metabolism. Curr Diabetes Rev. 2014 Nov 24;10(5):327–35.
35. Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018 Feb;20:5–21.
36. Venugopal SK, Sankar P, Jialal I. Physiology, Glucagon. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Dec 7]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK537082/>
37. Young A. Effects on Plasma Glucose and Lactate. In: Advances in Pharmacology [Internet]. Elsevier; 2005 [cited 2022 Dec 7]. p. 193–208. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1054358905520106>

38. Geidl-Flueck B, Gerber P. Insights into the Hexose Liver Metabolism—Glucose versus Fructose. *Nutrients*. 2017 Sep 16;9(9):1026.
39. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of Diabetes and Diabetes-Related Complications. *Phys Ther*. 2008 Nov 1;88(11):1254–64.
40. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes—2018*. *Diabetes Care*. 2018 Jan 1;41(Supplement_1):S13–27.
41. Zhang X, Imperatore G, Thomas W, Cheng YJ, Lobelo F, Norris K, et al. Effect of lifestyle interventions on glucose regulation among adults without impaired glucose tolerance or diabetes: A systematic review and meta-analysis. *Diabetes Res Clin Pract*. 2017 Jan;123:149–64.
42. Gounden V, Ngu M, Anastasopoulou C, Jialal I. Fructosamine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Dec 7]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK470185/>
43. Hoffman LS, Fox TJ, Anastasopoulou C, Jialal I. Maturity Onset Diabetes in the Young. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2022 Dec 7]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK532900/>
44. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA. *Mol Endocrinol*. 1991 Dec;5(12):1806–14.
45. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J Off Publ Fed Am Soc Exp Biol*. 1999 Jan;13(1):9–22.
46. Carmeliet P. Angiogenesis in health and disease. *Nat Med*. 2003 Jun 1;9(6):653–60.
47. Ferrara N, Gerber HP. The Role of Vascular Endothelial Growth Factor in Angiogenesis. *Acta Haematol*. 2001;106(4):148–56.

48. Kretzler M, Schröppel B, Merkle M, Huber S, Mundel P, Horster M, et al. Detection of multiple vascular endothelial growth factor splice isoforms in single glomerular podocytes. *Kidney Int.* 1998 Sep;54:S159–61.
49. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. *Dev Dyn.* 2001 Feb 1;220(2):112–21.
50. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. *Cancer Res.* 2002 Jul 15;62(14):4123–31.
51. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. *Diabetologia.* 2005 Nov;48(11):2422–7.
52. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, et al. VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant. *Cancer Res.* 2004 Nov 1;64(21):7822–35.
53. Bevan HS, van den Akker NMS, Qiu Y, Polman JAE, Foster RR, Yem J, et al. The Alternatively Spliced Anti-Angiogenic Family of VEGF Isoforms VEGF_{xxx}b in Human Kidney Development. *Nephron Physiol.* 2008 Nov 27;110(4):p57–67.
54. Simon M, Röckl W, Hornig C, Gröne EF, Theis H, Weich HA, et al. Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. *J Am Soc Nephrol.* 1998 Jun;9(6):1032–44.
55. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. *Kidney Int.* 2004 Jun;65(6):2003–17.

56. Cui TG, Foster RR, Saleem M, Mathieson PW, Gillatt DA, Bates DO, et al. Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF₁₆₅ b) mRNA and protein. *Am J Physiol-Ren Physiol*. 2004 Apr;286(4):F767–73.
57. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med*. 2003 Jun 1;9(6):669–76.
58. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. *Clin Sci*. 2005 Sep 1;109(3):227–41.
59. Gospodarowicz D, Abraham JA, Schilling J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. *Proc Natl Acad Sci*. 1989 Oct;86(19):7311–5.
60. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. *Proc Natl Acad Sci*. 1993 Nov 15;90(22):10705–9.
61. Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA. Differential Binding Characteristics and Cellular Inhibition by Soluble VEGF Receptors 1 and 2. *Exp Cell Res*. 1998 May;241(1):161–70.
62. Petrova TV, Makinen T, Alitalo K. Signaling via Vascular Endothelial Growth Factor Receptors. *Exp Cell Res*. 1999 Nov;253(1):117–30.
63. Robert B, Zhao X, Abrahamson DR. Coexpression of neuropilin-1, Flk1, and VEGF₁₆₄ in developing and mature mouse kidney glomeruli. *Am J Physiol-Ren Physiol*. 2000 Aug 1;279(2):F275–82.
64. Harper SJ, Xing CY, Whittle C, Parry R, Gillatt D, Peat D, et al. Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo. *Clin Sci Lond Engl 1979*. 2001 Oct;101(4):439–46.
65. Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocyte-Derived Vascular Endothelial Growth Factor Mediates the Stimulation of $\alpha 3$ (IV)

Collagen Production by Transforming Growth Factor- β 1 in Mouse Podocytes. Diabetes. 2004 Nov 1;53(11):2939–49.

66. Thomas S, Vanuystel J, Gruden G, Rodríguez V, Burt D, Gnudi L, et al. Vascular Endothelial Growth Factor Receptors in Human Mesangium *in Vitro* and in Glomerular Disease. J Am Soc Nephrol. 2000 Jul;11(7):1236–43.
67. Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous R, et al. Inducible Overexpression of sFlt-1 in Podocytes Ameliorates Glomerulopathy in Diabetic Mice. Diabetes. 2008 Oct 1;57(10):2824–33.
68. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels. J Vasc Res. 2000;37(6):443–8.
69. Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC. IDENTIFICATION OF POLYMORPHISMS WITHIN THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENE: CORRELATION WITH VARIATION IN VEGF PROTEIN PRODUCTION. Cytokine. 2000 Aug;12(8):1232–5.
70. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int. 2000 Sep;58:S104–12.
71. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes. 1999 Nov 1;48(11):2229–39.
72. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia Regulates Vascular Endothelial Growth Factor Gene Expression in Endothelial Cells: Identification of a 5' Enhancer. Circ Res. 1995 Sep;77(3):638–43.
73. Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int. 1995 Jul;48(1):20–32.

74. Chen S, Ziyadeh FN. Vascular endothelial growth factor and diabetic nephropathy. *Curr Diab Rep*. 2008 Dec;8(6):470–6.
75. Gröne HJ, Simon M, Gröne EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. *J Pathol*. 1995 Nov;177(3):259–67.
76. Nakagawa T. Uncoupling of VEGF with NO as a mechanism for diabetic nephropathy. *Diabetes Res Clin Pract*. 2008 Nov;82:S67–9.
77. Sun L, Yuan Q, Cao N, Guo W, Yao L, Feng JM, et al. VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: A meta-analysis. *Sci World J*. 2014;2014.
78. Zhang L, et al. Prevalence and factors associated with CKD: a population study from Beijing. *Am J Kidney Dis*. 2018;51(3):373-84.
79. Westhuyzen J. Cystatin C: A promising marker and predictor for impaired renal function. *Ann Clin Lab Sci*. 2016; 36: 387-94.
80. Elfiani E, Nasrul E, Yanwirasti Y, Ali Z, Puspasari A. Plasma Levels of the Engulfment and Cell Motility Protein-1 are Associated with Kidney Damage in Diabetic Nephropathy: A Single-Center Pilot Study in Indonesia Population. *Open Access Maced J Med Sci*. 2020 Jul 25;8(A):418–22.
81. Puspasari A, Elfiani E, Tarawifa S, Enis Rn, Hayani A. Genetic Variant Of Tgf- β Associated With Decreased Renal Function In Type Ii Diabetes Mellitus Patient: Single Center Pilot Study In Indonesia Study Design. 2021;53(4):319–28
82. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. *Am J Kidney Dis*. 2012; 40: 221-6
83. McKnight AJ, Maxwell AP, Patterson CC, Brady HR, Savage DA. Association of VEGF-1499C→T polymorphism with diabetic nephropathy in type 1 diabetes mellitus. *J Diabetes Complications*. 2007;21(4):242–5.

84. Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. *Graefe's Arch Clin Exp Ophthalmol*. 2009;247(1):21–6.
85. Li X, Lu Y, Wei P. Association between VEGF genetic variants and diabetic foot ulcer in Chinese Han population: A case–control study. *Medicine (Baltimore)*. 2018 May;97(20):e10672.